IN8bio, Inc. (INAB) vs Tempest Therapeutics, Inc. (TPST)
A side-by-side comparison of IN8bio, Inc. and Tempest Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INAB
IN8bio, Inc.
$1.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TPST
Tempest Therapeutics, Inc.
$0.79HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — INAB vs TPST
growth of $100 · dividends reinvested · last 5yINAB -99.5% (-65.7%/yr)TPST -99.6% (-67.0%/yr)INAB compounded faster over this window
INAB TPST
INAB vs TPST: by the numbers
- •INAB is the larger company ($13M vs $13M market cap).
Metrics side by side
Valuation
| Metric | INAB | TPST |
|---|---|---|
| P/B ratio | 0.73 | N/A |
Profitability
| Metric | INAB | TPST |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -101.66% | N/A |
| ROIC | -91.74% | -784.16% |
Growth (annualized)
| Metric | INAB | TPST |
|---|---|---|
| Total return CAGR (5Y) | -62.88% | -66.75% |
Frequently asked
- How have INAB and TPST total returns compared?
- Over the past 5 years, INAB delivered -62.88% and TPST delivered -66.75% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.